Skip to main content

Table 3 Crude and Adjusted a Incidence Rate Ratios for CVD Events by Exposure to Specific Antiretroviral Drugs

From: Traditional and HIV-specific risk factors for cardiovascular morbidity and mortality among HIV-infected adults in Brazil: a retrospective cohort study

  

Cumulative exposure

Recent exposure

 

N

cIRR

95 % CI

P

aIRR

95 % CI

P

cIRR

95 % CI

P

aIRR

95 % CI

P

ART

109

0.85

0.81–0.89

<0.001

0.79

0.75–0.83

<0.001

–

–

–

–

–

–

NRTI

109

0.85

0.81–0.89

<0.001

0.79

0.75–0.83

<0.001

–

–

–

–

–

–

Lamivudine

105

0.80

0.75–0.84

<0.001

0.76

0.72–0.81

<0.001

0.56

0.30–1.05

0.069

0.71

0.37–1.36

0.31

Zidovudine

93

0.86

0.81–0.91

<0.001

0.83

0.78–0.89

<0.001

1.27

0.86–1.89

0.23

1.34

0.90–2.00

0.15

Tenofovir

39

0.64

0.55–0.75

<0.001

0.60

0.51–0.71

<0.001

0.42

0.28–0.64

<0.001

0.37

0.24–0.56

<0.001

Stavudine

56

0.97

0.90–1.05

0.50

0.96

0.88–1.04

0.30

6.13

3.91–9.60

<0.001

5.28

3.18–8.75

<0.001

Didanosine

51

0.95

0.87–1.04

0.29

0.91

0.82–1.02

0.10

1.47

0.68–3.17

0.32

1.50

0.68–3.27

0.32

Emtricitabine

5

0.78

0.49–1.25

0.30

0.83

0.51–1.36

0.46

2.29

0.73–7.23

0.16

2.61

0.81–8.43

0.11

Abacavir

6

0.70

0.43–1.14

0.15

0.63

0.36–1.11

0.11

0.97

0.24–3.94

0.97

0.70

0.17–2.86

0.62

Zalcitabine

10

1.01

0.66–1.55

0.96

0.90

0.57–1.41

0.64

–

–

–

–

–

–

NNRTI

79

0.76

0.69–0.83

<0.001

0.77

0.70–0.85

<0.001

1.05

0.72–1.55

0.79

1.42

0.94–2.13

0.097

Efavirenz

67

0.75

0.67–0.84

<0.001

0.78

0.69–0.87

<0.001

0.90

0.60–1.34

0.59

1.25

0.81–1.93

0.31

Nevirapine

31

0.92

0.81–1.05

0.24

0.91

0.78–1.05

0.20

2.46

1.20–5.06

0.014

3.07

1.44–6.53

0.004

PI

79

0.92

0.88–0.96

0.001

0.88

0.83–0.93

<0.001

1.20

0.80–1.81

0.37

0.79

0.50–1.23

0.29

PI (without high dose RTV)

78

0.92

0.87–0.96

<0.001

0.87

0.83–0.92

<0.001

1.16

0.77–1.73

0.48

0.75

0.48–1.17

0.20

Ritonavir

35

0.91

0.78–1.05

0.20

0.84

0.71–1.01

0.061

4.05

2.05–8.03

<0.001

2.67

1.30–5.47

0.007

Lopinavir/

Ritonavir

41

0.86

0.76–0.96

0.009

0.81

0.71–0.92

0.001

1.20

0.79–1.84

0.40

0.90

0.58–1.39

0.64

Atazanavir + Ritonavir

13

0.60

0.45–0.79

<0.001

0.60

0.45–0.81

0.001

0.36

0.19–0.69

0.002

0.40

0.21–0.76

0.006

Darunavir + Ritonavir

6

0.71

0.50–1.02

0.067

0.65

0.45–0.95

0.027

0.64

0.28–1.46

0.29

0.47

0.20–1.09

0.08

Nelfinavir without booster

28

0.97

0.87–1.09

0.66

0.96

0.84–1.09

0.50

7.77

4.05–14.91

<0.001

5.32

2.60–10.88

<0.001

Indinavir without booster

39

1.05

0.95–1.16

0.35

1.00

0.89–1.11

0.98

11.56

5.84–22.90

<0.001

10.22

4.63–22.53

<0.001

Saquinavir + Ritonavir

4

0.55

0.15–2.0

0.37

0.47

0.11–2.12

0.33

1.63

0.23–11.68

0.63

1.05

0.14–7.58

0.97

Saquinavir without booster

24

0.90

0.71–1.13

0.35

0.82

0.62–1.08

0.15

3.96

1.46–10.76

0.007

2.07

0.71–6.00

0.18

Amprenavir + Ritonavir

3

1.55

0.82–2.93

0.18

1.37

0.66–2.85

0.39

–

–

–

–

–

–

Amprenavir without booster

4

0.85

0.42–1.73

0.66

0.64

0.28–1.49

0.30

9.62

1.34–68.95

0.024

3.88

0.52–28.89

0.19

Integrase Inhibitor

4

0.82

0.53–1.28

0.39

0.78

0.50–1.22

0.28

0.62

0.23–1.69

0.35

0.54

0.20–1.49

0.24

  1. Abbreviations: CVD cardiovascular disease, N number of participants with a CVD-related event exposed to the specific agent, cIRR crude incidence rate ratio, CI confidence interval, P p-value, ART combined antiretroviral therapy, NRTI nucleoside reverse transcriptase inhibitor, NNRTI non-NRTI, PI protease inhibitor, RTV ritonavir
  2. aFinal model was adjusted for specific ART agent or class; age ≥40 years; male sex; non-white race; nadir CD4+ T lymphocyte count ≤50 cells/mm3; virologic suppression; history of hypertension, dyslipidemia, or CVD; and calendar year of cohort entry
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us